What is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...

The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...

Indian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...

Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and player...

IOL Chemicals has approved a 1:5 stock split. This will increase affordability and liquidity. Shareholders will receive 5 new shares for ev...

Increasing incidence of fungal infections, greater awareness of skin-related issues and skin care and a growing desire to look presentable ...

Abbott in the second largest drug maker in India but it competes with Novartis in several therapy areas like cardiovascular, and diabetes. ...

Novartis India, with domestic sales of nearly Rs 1,200 crore, has been battling it out in the Indian market with several drug companies in ...

Alkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...

ZCL said it is a speciality pharma company focusing on niche therapeutic areas of central nervous system (CNS), anti-retroviral (ARV) and c...

Anti-infective cough and cold medication still tops the chart, with sales totalling Rs 14,735 crore in the domestic organised retail market.

According to data from AIOCD, the Indian pharma market has grown at a compound annual growth rate of 3.3% in volume terms in the past five ...

Novo is betting big on Tresiba in the emerging markets after it failed to get an approval for the drug from the US Food and Drug Administra...

French drug maker Sanofi says it is considering an India-specific strategy to increase its share in the country’s Rs 65,000-crore drug mark...

India, which is home to the largest diabetic population in the world, has recorded a 17% rise in the anti-diabetic drug segment.